Thanks to visit codestin.com
Credit goes to link.springer.com

Skip to main content
Springer Nature Link
Log in

Ciprofloxacin pharmacokinetics in patients with cystic fibrosis

Ciprofloxacin-Pharmakokinetik bei Patienten mit zystischer Fibrose

  • Originalia
  • Published:
Infection Aims and scope Submit manuscript

Summary

The pharmacokinetics of ciprofloxacin were studied in cystic fibrosis patients and healthy volunteers following oral administration of 500 mg and 1000 mg. Serum kinetics as well as urinary recovery were monitored. As the body weights of cystic fibrosis patients and the healthy volunteers differed significantly, kinetic parameters were calculated on the basis of a constant relative dose in mg/kg body weight. Neither serum kinetics nor urinary recovery differed significantly between the two groups, as indicated by the serum concentration versus time curves ranging from 1.1 to 1.4 mg × h/l, the elimination half-life of 4.4 to 5.1 h and the 24 h urinary recovery which amounted to 35% to 41% of the dose administered. Serum concentrations were linearly proportional to the doses administered. Sputum concentrations were monitored in cystic fibrosis patients. Again, ciprofloxacin sputum levels were linearly proportional to the doses and were within the same range as serum concentrations. Thus, ciprofloxacin kinetics are not altered in cystic fibrosis patients as compared to healthy volunteers.

Zusammenfassung

Die Ciprofloxacinkinetik wurde an Patienten mit zystischer Fibrose (CF) und gesunden Probanden nach oraler Gabe von 500 mg sowie 1000 mg untersucht. Die Serumkinetik und Harnwiederfindungsrate wurden bestimmt. Da das Körpergewicht der CF-Patienten einerseits und gesunden Probanden andererseits signifikant unterschiedlich ist, wurden die kinetischen Parameter auf der Basis einer konstanten relativen Dosis in mg/kg Körpergewicht berechnet. Weder die Serumkinetik noch Urinwiederfindungsrate waren in den beiden Gruppen signifikant unterschiedlich. Die standardisierte Fläche unter der Serumspiegel-versus Zeitkurve betrug 1,1 bis 1,4 mg × h/l, die Eliminationshalbwertszeit schwankte zwischen 4,4 und 5,1 h, und die 24-Std.-Harnwiederfindungsrate belief sich auf 35 bis 41% der verabreichten Dosis. Die Serumkonzentrationen waren linear proportional zu den verabreichten Dosen. Die Sputumkonzentrationen wurden in CF-Patienten bestimmt. Wiederum waren die Sputumkonzentrationen linear proportional zur verabreichten Dosis und lagen im gleichen Konzentrationsbereich wie auch die Serumkonzentrationen. Somit ist die Ciprofloxacinkinetik in CF-Patienten im Vergleich zu gesunden Probanden nicht verändert.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+
from £29.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

Literatur

  1. Bauernfeind, A., Petermüller, C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur. J. Clin. Microbiol. 2 (1983) 111–115.

    Google Scholar 

  2. Wise, R., Andrews, J. M., Edwards, L. J. In vitro activity of BAY o 9867, a new quinolone derivative, compared with those of other antimicrobial agents. Antimicrob. Agents Chemother. 23 (1983) 559–564.

    Google Scholar 

  3. Chin, N. X., Neu, H. C. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 25 (1984) 319–326.

    Google Scholar 

  4. Zeiler, H. J., Grohe, K. Thein vitro andin vivo activity of ciprofloxacin. Eur. J. Clin. Microbiol. 3 (1984) 339–343.

    Google Scholar 

  5. Hoogkamp-Korstanje, J. A. A. Comparativein vitro activity of five quinolone derivatives and five other antimicrobial agents used in oral therapy. Eur. J. Clin. Microbiol. 3 (1984) 333–338.

    Google Scholar 

  6. Shrire, L., Saunders, J., Traynor, R., Koorhof, H. J. A laboratory assessment of cirpofloxacin and comparable antimicrobial agents. Eur. J. Clin. Microbiol. 3 (1984) 328–332.

    Google Scholar 

  7. Wingender, W., Graefe, K.-H., Gau, W. Förster, D., Beermann, D., Schacht, P. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur. J. Clin. Microbiol. 3 (1984) 355–359.

    Google Scholar 

  8. Höffken, G., Lode, H., Prinzing, C., Borner, K., Koeppe, P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob. Agents Chemother. 27 (1985) 375–379.

    Google Scholar 

  9. Wise, R., Lockley, R. M., Webberly, M., Dent, J. Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob. Agents Chemother. 26 (1984) 208–210.

    Google Scholar 

  10. Boerema, J. B. J., Dalhoff, A., Debruyne, F. M. Y. Intraprostatic concentrations of ciprofloxacin following intravenous administration. Lancet II (1984) 695–696.

    Google Scholar 

  11. Boerema, J. B. J., Dalhoff, A., Debruyne, F. M. Y. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy (Basel) 31 (1985) 13–18.

    Google Scholar 

  12. Hoogkamp-Korstanje, J. A. A., van Oort, H. J., Schipper, J. J., van der Wal, T. Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens. J. Antimicrob. Chemother. 14 (1984) 641–645.

    Google Scholar 

  13. Dalhoff, A., Eickenberg, H. U. Tissue distribution of ciprofloxacin following oral and intravenous administration. Infection 13 (1985) 78–81.

    Google Scholar 

  14. Dalhoff, A., Weidner, W. Diffusion of ciprofloxacin into prostatic fluid. Eur. J. Clin. Microbiol. 3 (1984) 360–362.

    Google Scholar 

  15. Falser, N., Dalhoff, A., Weuta, H. Ciprofloxacin concentrations in tonsils following a single intravenous administration. Infection 12 (1984) 355–357.

    Google Scholar 

  16. Goormans, E., Dalhoff, A., Kazzaz, B., Branolte, J.: Penetration of ciprofloxacin into gynaecological tissues following oral and intravenous administration. Chemotherapy (Basel) 1986 (in print).

  17. Höffler, D., Dalhoff, A., Gau, W., Beermann, D., Michl, A. Dose- and sex-independent disposition of ciprofloxacin. Eur. J. Clin. Microbiol. 3 (1983) 363–366.

    Google Scholar 

  18. Michalsen, H., Bergan, T. Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis. Scand. J. Infect. Dis. S29 (1981) 92–97.

    Google Scholar 

  19. Michaelsen, H., Bergan, T. Pharmacokinetics of antibiotics in children with cystic fibrosis with particular reference to netilmicin. Acta Pediatr. Scand. S301 (1982) 101–105.

    Google Scholar 

  20. Bergan, T., Michalsen, H. Pharmacokinetics of azolcillin in children with cystic fibrosis. Arzneim.-Forsch./Drug Res. 29 (1979) 1955–1957.

    Google Scholar 

  21. Kearns, G. L., Hilman, B. C., Wilson, J. T. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J. Pediatr. 100 (1982) 312–318.

    Google Scholar 

  22. Kelly, H. B., Menendez, R., Fau, L., Murphy, S. Pharmacokinetics of tobramycin in cystic fibrosis. J. Pediatr. 100 (1982) 318–321.

    Google Scholar 

  23. Hoogkamp-Korstanje, J. A. A., van der Laag, J. Piperacillin and tobramycin in the treatment of pseudomonas lung infections in cystic fibrosis. J. Antimicrob. Chemother. 12 (1983) 175–183.

    Google Scholar 

  24. Reed, M. D., Bertino, J. S., Aronoff, S. C., Husak, M. P., Blumer, J. L., Speck, W. T.: Efficacy and pharmacokinetics of piperacillin in patients with cystic fibrosis. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, November 1981, Abstract No. 403.

  25. Jusko, W. J., Mosovich, L. L., Gerbracht, M. S., Mattar, M. E., Yaffe, S. J. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics 56 (1975) 1038–1044.

    Google Scholar 

  26. Jusko, W. J., Gerbracht, L., Mattar, M. E., Mosovich, L., Yaffe, S. J. Pharmacokinetics of dicloxacillin in patients with cystic fibrosis. Clin. Pharmacok. Ther. 15 (1974) 209–210.

    Google Scholar 

  27. Yaffe, S. J., Gerbracht, L. M., Mosovich, L. L., Matter, M. E., Danish, M., Jusko, W. J. Pharmacokinetics of methicillin in patients with cystic fibrosis. J. Infect. Dis. 135 (1977) 828–831.

    Google Scholar 

  28. Turner, A., Pedler, S. J., Carwell, F., Spencer, G., R., Speller, D. C. E. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis. J. Antimicrob. Chemother. 14 (1984) 521–527.

    Google Scholar 

  29. Reed, M. D., Stern, R. C., Yamashita, T. S., Ackers, I., Myers, C. M., Blumer, J. L. Single dose pharmacokinetics of cefsulodin with cystic fibrosis. Antimicrob. Agents Chemother. 25 (1984) 579–581.

    Google Scholar 

  30. Arvidsson, A. G., Alvan, G., Strandvik, B. Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal controls. Acta Paediatr. Scand. 72 (1983) 293–294.

    Google Scholar 

  31. Reed, M. D., Stern, R. C., O'Brian, C. A., Yamashiha, T. S., Myers, C. M., Blumer, J. L. Pharmacokinetics of imipenem and celastin in patients with cystic fibrosis. Antimicrob. Agents Chemother. 27 (1985) 583–588.

    Google Scholar 

  32. Bosso, J. A., Saxon, B. A., Herbst, J. J., Matsen, J. M. Azlocillin pharmacokinetics in patients with cystic fibrosis. Antimicrob. Agents Chemother. 25 (1984) 630–632.

    Google Scholar 

  33. Shah, P. M., Strehl, R., Posselt, H. G., Bender, S. W. Ciprofloxacin bei Mucoviszidose — zystische Fibrose (CF), eine pharmakokinetische Untersuchung. Fortschr. Antimikr. Antineoplast. Chemother. 3 (1984) 685–690.

    Google Scholar 

  34. Brittain, D. C., Scully, B. E., Lobthavikul, P., McElrath, M. J., Neu, H. C.: The pharmacokinetics and bactericidal activity of ciprofloxacin (BAY o 9867) compared to cotrimoxazole. 4th Mediterranean Congress of Chemotherapy, Rhodos, October 1984, Abstract No. 619.

  35. Ledergerber, B., Beltex, J. D., Joos, B., Flepp, M., Lüthy, R. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob. Agents Chemother. 27 (1985) 350–352.

    Google Scholar 

  36. Brumfitt, W., Franklin, I., Grady, D., Hamilton-Miller, J. M. T., Iliffe, A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob. Agents Chemother. 26 (1984) 757–761.

    Google Scholar 

  37. Bergan, T., Delin, C., Johansen, S., Kolstad, I. M., Nord, C. E., Thorsteinsson, S. B.: Stable steady state pharmacokinetics and the effect of ciprofloxacin on salivary and fecal microflora during repeated dosage. Antimicrob. Agents Chemother. 1986 (in print).

  38. Crump, B., Wise, R., Dent, J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob. Agents Chemother. 24 (1983) 784–786.

    Google Scholar 

  39. Goldfarb, J., Wormser, G. P., Inchiosa, M. A., Guideri, G., Diaz, M., Gandhi, R., Goltzman, C., Mascia, A. K.: Single dose pharmacokinetic study of oral ciprofloxacin in young adults with cystic fibrosis. 14th International Congress of Chemotherapy, Kyoto, June 1985, Abstract No. S40-13.

  40. Schlenkhoff, D., Mayer, M., Dalhoff, A.: Penetration of ciprofloxacin into human lung tissue following a single intravenous administration. 14th International Congress of Chemotherapy, Kyoto 1985, Abstract No. S40-11.

  41. Bergogne-Bérézin, E., Berthelot, G., Even, P., Dennewald, G., Stern, M.: Pharmacokinetics of ciprofloxacin study of its distribution in the respiratory secretions. 14th International Congress of Chemotherapy, Kyoto 1985, Abstract No. S40-10.

  42. Ullmann, U., Giebel, W., Dalhoff, A., Koeppe, P.: Single and multiple dose pharmacokinetics and penetration activities of ciprofloxacin. J. Antimicrob. Chemother. 1986 (in print).

  43. Bender, S. W., Posselt, H. G., Wönne, R., Stöver, B., Strehl, R., Shah, P. M.: Oral ciprofloxacin for Pseudomonas bronchopneumonia in CF. Proceedings of the 9th International Cystic Fibrosis Congress, Brighton, June 1984, Abstract No. 4.25.

  44. Bender, S. W., Shah, P. M., Strehl, R., Posselt, H. G.: Distribution kinetics of ciprofloxacin for evaluation of therapeutic efficacy in Pseudomonas bronchopneumonia in CF patients. 14th International Congress of Chemotherapy, Kyoto, June 1985, Abstract No. S51-8.

  45. Sörgel, F., Stephan, U., Wiesemann, H. G., Brüning, I., Dominick, H. C., Hesseling, C.: The pharmacokinetics of ciprofloxacin in cystic fibrosis and healthy volunteers. 14th International Congress of Chemotherapy, Kyoto, June 1985, Abstract No. S40-12.

  46. Sörgel, F., Stephan, U., Wiesemann, H. G., Dominick H. C., Boewing, B. Pharmacokinetics of antibiotics in cystic fibrosis. Eur. J. Pediatr. 143 (1985) 249.

    Google Scholar 

  47. Blumer, J. L., Stern, R. C., Myers, C. M., Klinger, J. D., Reed, M. D.: Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis. 14th International Congress of Chemotherapy, Kyoto, June 1985, Abstract No. S40-14.

  48. Le Bel, M., Vallée, F., Fiset, C., Bigonesse, P., Rivard, G., Bergeron, M. G.: Pharmacokinetics of ciprofloxacin in cystic fibrosis patients. Assemblée annuelle CRMC du Canada et les sociétés.

Download references

Author information

Authors and Affiliations

  1. Abteilung für Allgemeine Pädiatrie I, Zentrum der Kinderheilkunde, Theodor-Stern-Kai 7, D-6000, Frankfurt am Main 70

    S. W. Bender &  H. G. Posselt

  2. Bayer AG, Pharma Research Center, D-5600, Wuppertal

    A. Dalhoff

  3. Zentrum der Inneren Medizin, Theodor-Stern-Kai 7, D-6000, Frankfurt am Main 70

    P. M. Shah &  R. Strehl

Authors
  1. S. W. Bender
    View author publications

    Search author on:PubMed Google Scholar

  2. H. G. Posselt
    View author publications

    Search author on:PubMed Google Scholar

  3. A. Dalhoff
    View author publications

    Search author on:PubMed Google Scholar

  4. P. M. Shah
    View author publications

    Search author on:PubMed Google Scholar

  5. R. Strehl
    View author publications

    Search author on:PubMed Google Scholar

Additional information

This paper is dedicated to Prof. Dr.O. Hövels on the occasion of his 65th birthday.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bender, S.W., Posselt, H.G., Dalhoff, A. et al. Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. Infection 14, 17–21 (1986). https://doi.org/10.1007/BF01644804

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01644804

Keywords